STOCK TITAN

CII Holds 9.89M Shares of agilon health, Discloses 2.4% Ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Capital International Investors reported beneficial ownership of 9,892,742 shares of agilon health common stock, equal to 2.4% of 413,951,779 shares outstanding. CII is presented as a division of Capital Research and Management Company and affiliated investment management entities and states it has sole voting and sole dispositive power over those 9,892,742 shares with no shared power. The disclosure is filed on a Schedule 13G/A as an IA (investment adviser) and the filing notes this is an ownership position of 5% or less. The signer certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Institutional investor reports a modest 2.4% passive stake with sole voting and dispositive power; not a control position.

The filing shows Capital International Investors beneficially owns 9,892,742 shares of agilon health, representing 2.4% of the 413,951,779 shares the filing cites as outstanding. The holder reports sole voting and dispositive authority for the full position and files on Schedule 13G/A as an investment adviser, which is consistent with passive disclosure requirements. Because the stake is under 5% and the certification states the position is held in the ordinary course and not to influence control, the holding is unlikely to materially affect agilon's governance or near-term valuation.

TL;DR: Governance impact appears minimal: no shared power, no group affiliation, certification denies control intent.

The statement specifies zero shared voting or dispositive power and does not identify any group or subsidiary acquiring the securities, reducing the likelihood of coordinated governance action. The filer classifies itself as type IA (investment adviser) and includes the standard certification that the securities are not held to change or influence control. From a governance perspective, this disclosure documents institutional ownership but does not signal active engagement or a control attempt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Capital International Investors
Signature:Jae Won Chung
Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
Date:08/12/2025

FAQ

What stake does Capital International Investors report in agilon health (AGL)?

Capital International Investors reports beneficial ownership of 9,892,742 shares, representing 2.4% of 413,951,779 shares outstanding.

Does Capital International Investors share voting or dispositive power over the reported shares?

No. The filing reports sole voting power and sole dispositive power for 9,892,742 shares and 0 shared voting or dispositive power.

Under which SEC form and classification was this disclosure filed for AGL?

The disclosure was made on a Schedule 13G/A and the reporting person is classified as an IA (investment adviser).

Is the Capital International stake in agilon health greater than 5%?

No. Item 5 indicates ownership of 5 percent or less of the class; the reported stake is 2.4%.

Who signed the Schedule 13G/A on behalf of Capital International Investors?

The filing is signed by Jae Won Chung, Vice President and Senior Counsel II at Capital Research and Management Company.
Agilon Health Inc

NYSE:AGL

AGL Rankings

AGL Latest News

AGL Latest SEC Filings

AGL Stock Data

255.35M
308.23M
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
WESTERVILLE